We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Stay up to date on the topics that matter to you

IsoPlexis

IsoPlexis is dedicated to accelerating the fight against cancer and a range of our toughest diseases by producing the world’s most precise, award-winning detection systems. By revealing unique immune biomarkers in small subsets of cells, they are advancing immunotherapies and targeted therapies to a more precise and personalized stage.

Latest IsoPlexis Content

Industry Insight

Identifying Risk Factors for Long COVID With Single-Cell Proteomics

In this interview we speak to Sean Mackay, CEO of IsoPlexis, to discuss how single-cell functional proteomics have helped researchers understand the risk factors behind long COVID.

Never miss a story

with the Breaking Science News daily newsletter